Actively including Crohn’s Disease Studies

Gilead/Galapagos GS-US-419-3895 (JAK1 inhibitor, filgotinib):

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease

Gilead/Galapagos GS-US-419-3896:

A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease

Boehringer Ingelheim 1368-0008 (IL36-R antagonist, BI655130):

Mechanism of Action and Clinical Effect of BI655130 in Patients with fistulizing Crohn’s Disease

Love CD (anti α4β7-integrine, Vedolizumab early use):

An open label interventional phase 4 study to Evaluate Efficacy, Safety and Mucosal Healing of early use of vedolizumab in Crohn's disease: the LOVE-CD study (LOw countries VEdolizumab in CD study)

Pfizer B7981007 / Pizzicato (TYK2JAK1 & JAK3):

A Phase IIA, double blind, randomized, placebo controlled, parallel group study to evaluate the efficacy and safety of oral PF-06651600 (JAK3) and PF-06700841 (TYK2 and JAK1) as induction and open label extension treatment in subjects with moderate to severe Crohn’s disease

RPC01-3201 / Receptos (activates S1P1 and S1P5R, Ozanimod):

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease

RPC01-3203 / Receptos

A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease

RPC01-3204 / Receptos

A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod For Moderately to Severely Active Crohn’s Disease

Tigenix Admire CD II (locale stem cell treatment for complex fistulas):

A phase III, randomized, double blind, parallel group, placebo controlled, international, multicenter study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC), for the treatment of complex perianal fistula(s) in patients with Crohn’s disease over a period of 24 weeks and a follow-up period up to 52 weeks.

BIRD / Credo 2 (testing for a new score for endoscopic remission):

Is the endoscopic remission evaluation, using the CREDO 1 index / score in CD patients in clinical remission at baseline, predictive of sustained clinical remission using a 2-year follow up: a multicenter prospective cohort study

REScUE (anti IL12/IL23, Ustekinumab):

Using a re-induction with Stelara® (ustekinumab) by intravenous administration followed by 4- or 8-week subcutaneous administration of Stelara® for the treatment of loss of response with the registered posology of Stelara® for the treatment of Crohn.

AMAM (Mirikizumab)

A phase 3, multicenter, randomized, double-blind, placebo- and active-controlled, treat-through study to evaluate the efficacy and safety of Mirikizumab in patients with moderately to severely active Crohn’s disease

Alofisel 5003 / Inspire (stem cells, darvadstrocel):

An observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with crohn’s disease and complex perianal fistulas